ReAlta Life Sciences, Inc., founded in late 2018 and based in Norfolk, Virginia, is a pharmaceutical company specializing in immune system therapies. Formed as a joint venture between Children’s Hospital of The King’s Daughters, Children’s Specialty Group, and Eastern Virginia Medical School, ReAlta focuses on developing treatments for rare diseases by rebalancing the inflammatory response. Their product pipeline includes therapies for conditions such as Hypoxic Ischemic Encephalopathy, Acute Exacerbations of COPD, Graft-versus-Host Disease, and Platelet Refractoriness.

Notable affiliates include the founding institutions and a team of experienced management and scientific advisors. ReAlta has made significant strides in its clinical pipeline, advancing several therapies into clinical stages. Their innovative approach to immune modulation has the potential to transform treatment paradigms for rare and severe inflammatory conditions, marking a substantial impact on both patient outcomes and the broader pharmaceutical landscape.